Pharmaceutical Microbiology Market Size & Share, by Product Type (Pharmaceutical, Biopharmaceutical); Services (Microbial Identification, Antimicrobial Effectiveness, Stability Studies, Validation of Microbial Recovery, MIC Evaluations, MBC Evaluations); Tests (Endotoxin & Sterility Testing, Microbial Examination, Environmental Monitoring); End-user (Pharmaceutical, Biotechnology, Academic & Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5870
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Pharmaceutical Microbiology Market size is expected to reach USD 18 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of pharmaceutical microbiology was over USD 6 Billion. The market for pharma microbiology is primarily driven by the rise in the prevalence of infectious disorders. Infectious diseases such as sexually transmitted infections (STDs), HIV, and infectious diseases like hepatitis A, B, and C are becoming more commonplace worldwide. For instance, globally 39 million people [33.1 million-45.7 million] were HIV positive in 2022. The market for pharma microbiology is therefore driven by the rising number of infectious illness cases brought on by contaminated needle injections, unprotected sex, homelessness, lack of access to healthcare, and other socioeconomic difficulties.

Furthermore, regulatory agencies such as the FDA and EMA, have stringent guidelines mandating the sterility of pharmaceutical products to ensure patient safety. Compliance with these regulations necessitates throughout the manufacturing process, driving the demand for microbiology services and products. Also, maintaining sterility is essential for preserving the efficacy and safety of pharmaceutical products. Therefore, these factors are accelerating the growth of the market.

Pharmaceutical Microbiology Market
Get more information on this report: Request Free Sample PDF

Pharmaceutical Microbiology Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Investment in the Healthcare Infrastructure - As healthcare infrastructure expands, more people gain access to healthcare services, leading to increased demand for pharmaceutical products. Also, investment in healthcare infrastructure often aims to address public health challenges, such as infectious diseases and antimicrobial resistance. For instance, the 2023 report provides fresh insights into the development of global health spending during the peak of the COVID-19 pandemic. The analysis, which was released in advance of Universal Health Coverage (UHC) Day, shows that, in 2021, health spending worldwide hit a record high of USD 9.8 trillion, or 10.3% of the world's gross domestic product (GDP). Still, there was a glaring disparity in the way that expenditure was distributed. Globally, public health spending has increased, which is propelling the growth of the pharmaceutical microbiology market
  • Growing Demand for Sterility of the Products - Sterile testing is required to guarantee the safety and effectiveness of biopharmaceuticals, such as cell treatments, monoclonal antibodies, and vaccines, due to the increasing demand for these products. For instance, the stem cell therapy industry was estimated to be worth approximately 755 million US dollars globally in 2018, and it is anticipated to grow to over 11 billion dollars by 2029. To avoid pharmaceutical items from harming patients and causing infections and other health issues, sterility is essential. Additionally, keeping pharmaceutical products sterile is crucial to preserving their quality and integrity over the course of their shelf life and guaranteeing that they are safe and effective for use by patients.
  • Growing Technological Advancements- The rapid on-site identification of microbiological contaminations made possible by advancements in point-of-care testing technologies allows for prompt decision-making and intervention to prevent contamination in pharmaceutical manufacturing facilities. Furthermore, high-throughput screening of microbiological samples with low reagent usage is made possible by miniaturized platforms and microfluidic devices, which makes them perfect for large-scale testing in pharmaceutical labs. Additionally, real-time monitoring, trend analysis, and predictive modeling of the dangers associated with microbial contamination are made possible by the integration of microbiological technologies with data analytics and artificial intelligence, which is propelling the market's expansion.


  • Limited Shelf Life of Microorganisms and Microbiology Reagents - The duration of microbiology reagents' shelf life is contingent upon their exposure to ambient conditions. Because microorganisms, like bacteria, have a short lifespan (12 hours), there is very little time for microbiological study because the microorganisms' quality deteriorates and they become inappropriate for use, leading to erroneous results from pharma microbiology testing kits. Thus, the limited or brief shelf life of microbiological reagents may result in higher expenses and hamper the growth of the pharmaceutical microbiology market.
  • Emergence of New Microbial Pathogens and Drug-resistant Strains may Hinder the Growth of the Market
  • Complexity of Manufacturing Processes of the Biologics and Advanced Therapies which may Act as a Hindrance to the Market Growth

Pharmaceutical Microbiology Market: Key Insights

Base Year


Forecast Year



~ 9%

Base Year Market Size (2023)

 ~ USD 6 Billion

Forecast Year Market Size (2036)

 ~ USD 18 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Pharmaceutical Microbiology Segmentation

Product Type (Pharmaceutical, Biopharmaceutical)

The biopharmaceutical segment in the pharmaceutical microbiology market is expected to grow with the largest share of 54% during the forecast period. As biopharmaceuticals are made using living microbes and animal cells, they have a high therapeutic value and can effectively cure a wide range of chronic illnesses, including diabetes, cancer, cardiovascular disease, Parkinson's disease, and many more. Furthermore, as the worldwide geriatric population ages and becomes more susceptible to chronic illnesses, the need for biologic medications is expected to rise. Also, pharmaceutical companies are investing heavily in the research and development of biological drugs, leading to an expanding pipeline of innovative therapies targeting various diseases. For instance, the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) introduced by Novartis to treat moderate to severe hidradenitis suppurative (HS) in adults. The only fully human biologic licensed by the FDA that directly inhibits interleukin-17A (IL-17A), a cytokine thought to be implicated in HS inflammation, is Cosentyx.2.

Service (Microbial Identification, Antimicrobial Effectiveness, Stability Studies, Validation of Microbial Recovery, Minimum Inhibitory Concentration (MIC) Evaluations, Minimum Bactericidal Concentration (MBC) Evaluations)

Pharmaceutical Microbiology Market for the microbial identification segment is expected to hold a share of 35% by the end of 2036. With the expanding complexity of pharmaceutical manufacturing processes and the worldwide nature of supply chains, pharmaceutical companies are increasingly concerned about microbial contamination. As a result, there is a growing emphasis on microbiological identification to detect and treat contamination issues promptly, ensuring product quality and safety. Furthermore, technological advancements have resulted in the development and acceptance of rapid microbiological techniques (RMM) for microbial identification, which is expected to rise further in the future. Furthermore, the advent of new microbial diseases is also propelling the growth of the segment. Some microbial diseases include tuberculosis, Lyme disease, measles, malaria, fungal diseases, and others. According to the most recent estimates, there are 476,000 new Lyme cases in the United States each year, and is expected to increase by 59% by 2021. Scientists predict that two million people will suffer from post-treatment Lyme disease by the end of 2020. Microbial identification is critical for tracking and characterizing these infections to establish effective control measures and treatment plans.

Our in-depth analysis of the global market includes the following segments:


  • Pharmaceutical
  • Biopharmaceutical


  • Microbial Identification
  • Antimicrobial Effectiveness
  • Stability Studies
  • Validation of Microbial Recovery
  • Minimum Inhibitory Concentration (MIC) Evaluations
  • Minimum Bactericidal Concentration (MBC) Evaluations


  • Endotoxin Testing
  • Sterility Testing
  • Microbial Examination
  • Environmental Monitoring


  • Pharmaceutical
  • Biotechnology
  • Academic & Research Institutes

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Pharmaceutical Microbiology Industry - Regional Synopsis

North American Market Forecast

The North American pharmaceutical microbiology market is poised to account for the largest share of 36% during the forecast period. Due to its better health care system and stringent regulations, the region has a higher demand for pharmaceutical microbiology products. Moreover, innovation in testing technologies is encouraged by the existence of large research and development, biotechnology, and pharmaceutical companies. Other factors contributing to the growth of the market in this region include an aging population, as well as increasing incidences of infectious diseases in the region such as HIV and Influenza. For instance, in the US approximately 25,000 people died from the disease during the flu season in 2019-2020.

APAC Market Statistics

The Pharmaceutical Microbiology Market in the Asia Pacific region is anticipated to hold a share of 28% during the foreseen period. The rapid growth of economies in Asia Pacific countries has led to increased expenditure on health care, which is driving demand for pharmaceutical products. Moreover, the growth of the market in the region is driven by growing investments in biotechnology and increasing demand for biologics. Moreover, factors such as the availability of skilled labor and supportive regulatory environments have made this region a key hub for pharmaceutical manufacturing activities.

Research Nester
Pharmaceutical Microbiology Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Pharmaceutical Microbiology Landscape

    • NEOGEN Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Hardy Diagnostics
    • IDEXX
    • Charles River Laboratories
    • BioMerieux SA
    • Merck KGAA
    • Rapid Micro Biosystems.
    • Abbott Laboratories, Inc
    • Bio-Rad Laboratories
    • Gen-Probe, Inc


In The News

  • An innovative test system from NEOGEN Corporation may identify microorganisms automatically in a fraction of the time it takes with conventional testing techniques. The novel Soleris® Next Generation (NG) from NEOGEN is capable of quickly identifying a broad range of bacteria that may jeopardize the quality and safety of food and other consumer goods. For instance, whereas traditional methods require three to five days to identify and count yeast and mold in a sample, Solaris NG can do so in just 48 hours. Additionally, it can identify Alicyclobacillus, a bacterium of special concern to the fruit juice industry, in just 48 hours as opposed to five days using other methods.
  • The CompactDry TCR, a ready-to-use dehydrated culture medium plate from Hardy Diagnostics, is designed to identify and count microorganisms. It can yield total aerobic plate counts in as little as 24 hours. Being AOAC PTM (Association of Official Analytical Chemists - Performance Tested Methods) approved, this self-diffusing plate is the simplest to use for plate counts since it doesn't require spreading or stamping. Just take off the lid, pour 1 milliliter of sample onto the middle of the plate, replace the lid, and let it incubate.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5870
  • Published Date: Mar 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing investment in the healthcare infrastructure, growing demand for sterility of the products, and growing technological advancements are the major factors driving the growth of the pharmaceutical microbiology market.

The market size of pharmaceutical microbiology is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are NEOGEN Corporation, Hardy Diagnostics, IDEXX, Charles River Laboratories, BioMerieux SA, Merck KGAA, Rapid Micro Biosystems., Abbott Laboratories, Inc., Bio-Rad Laboratories, Gen-Probe, Inc., and others.

The biopharmaceutical segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Pharmaceutical Microbiology Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying